Ranking · Unmet Need
Trial Gap Index
Burden percentile minus active-trial percentile within the same scope. Positive values flag cancers with high mortality burden but comparatively few active trials. A quantitative signal, not an accusation (CLAUDE.md §324). Caveat (Phase 1): trial counts aggregate a cancer and its NCIt descendants only; registrations phrased at a broader level (e.g. "colorectal cancer" for colon and rectal cancer) are attributed to the broader entity, which can overstate the gap of narrower top-level sites.
Computedci-trial-gap-v1unit: percentile pointshigher = worseAll metrics
| Rank | Δ | Cancer | Trial Gap Index (percentile points) | Percentile | Confidence | Sources | Why #n? |
|---|---|---|---|---|---|---|---|
| 1 | = | Malignant Colon Neoplasm | +56.7 | 100 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2600374 |
| 2 | = | Malignant Bladder Neoplasm | +23.3 | 96.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2600375 |
| 3 | = | Cutaneous Melanoma | +20 | 93.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2600376 |
| 4 | = | Malignant Laryngeal Neoplasm | +16.7 | 90 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2600377 |
| 5 | = | Malignant Vulvar Neoplasm | +13.4 | 86.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2600378 |
| 6 | = | Malignant Pancreatic Neoplasm | +10 | 83.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2600379 |
| 6 | = | Malignant Vaginal Neoplasm | +10 | 83.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2600380 |
| 8 | = | Malignant Esophageal Neoplasm | +3.4 | 76.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2600381 |
| 9 | = | Malignant Salivary Gland Neoplasm | +3.3 | 73.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2600382 |
| 10 | = | Malignant Kidney Neoplasm | +3.3 | 70 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2600384 |
| 10 | = | Malignant Mesothelioma | +3.3 | 70 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2600383 |
| 12 | = | Malignant Liver Neoplasm | 0 | 63.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2600386 |
| 12 | = | Malignant Lung Neoplasm | 0 | 63.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2600385 |
| 12 | = | Malignant Prostate Neoplasm | 0 | 63.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2600387 |
| 12 | = | Malignant Rectal Neoplasm | 0 | 63.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2600389 |
| 12 | = | Malignant Testicular Neoplasm | 0 | 63.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2600388 |
| 17 | = | Malignant Thyroid Gland Neoplasm | -3.3 | 46.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2600390 |
| 18 | = | Malignant Breast Neoplasm | -3.4 | 43.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2600391 |
| 18 | = | Malignant Central Nervous System Neoplasm | -3.4 | 43.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2600392 |
| 20 | = | Malignant Anal Neoplasm | -6.6 | 36.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2600393 |
| 21 | = | Malignant Hypopharyngeal Neoplasm | -6.7 | 33.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2600394 |
| 21 | = | Malignant Penile Neoplasm | -6.7 | 33.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2600395 |
| 23 | = | Malignant Ovarian Neoplasm | -6.7 | 26.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2600396 |
| 24 | = | Leukemia | -10 | 23.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2600397 |
| 24 | = | Malignant Uterine Corpus Neoplasm | -10 | 23.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2600398 |
| 26 | = | Hodgkin Lymphoma | -13.4 | 16.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2600399 |
| 27 | = | Malignant Gastric Neoplasm | -13.4 | 13.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2600400 |
| 28 | = | Multiple Myeloma | -16.6 | 10 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2600401 |
| 28 | = | Non-Hodgkin Lymphoma | -16.6 | 10 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2600402 |
| 30 | = | Malignant Cervical Neoplasm | -20 | 3.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2600403 |
| 31 | = | Malignant Nasopharyngeal Neoplasm | -30 | 0 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2600404 |
Data updated 16 hours agoSource updated unknown31 eligible entities · inputs hash f06d08edd50dc77d23b6f20b